

# Schloss Wachenheim AG

Germany / Food & beverages Primary exchange: Frankfurt Bloomberg: SWA GR ISIN: DE0007229007

Q2 20/21 results

RATING PRICE TARGET

BUY € 21.00

Return Potential 41.9% Risk Rating Medium

# ROBUST, PANDEMIC-DEFYING PERFORMANCE

Q2 sales at €117.9m (Q2 19/20: €118.6m; FBe: €115.5m) were onlyslightly (0.6%) below the prior year period figure, while EBIT, which jumped 23.2% to €15.6m (Q2 19/20: €12.7m; FBe: €14.5m) was 7.7% abore our forecast. The German market accounted for most of the difference between the reported result and our forecast. Organic volume growth in Germany was negative during the prior year quarter but in Q2 20/21 came in at 10.4% with positive contributions from both branded and private label products. Profitability across the group was helped by reduced advertising expenditure (a €3.5m cut during the first six months) as well as by tight control of other operating costs in Germany and France. Consumer sentiment has deteriorated since Christmas and hotels and restaurants are unlikely to make a full return as clients in the near term. Nevertheless, robust performance during the critical Christmas quarter has prompted management to raise guidance for full-year EBIT and profit before minorities to €19.5m-€21.5m (previously: €18.0m-€200m) and €13.5m-€15.5m (previously: €12.5n-€14.5m) respectively. Full-year guidance for stable sales and volume remains unchanged. Based on these upward revisions, we have raised our price target from €20.00 to €21.00. Our recommendation is to Buy the share now for post-pandemic recovery.

Volume in Germany up 10.4% Volume in Germany rose 10.4% to 27.1m bottles (Q2 19/20: 24.5m bottles) while sales climbed 11.3% to €43.5m (Q2 19/20: €39.1m). These increases were above our expectations but should be seen against the background of the weak prior year figures and also the fact that full lockdown did not begin in Germany until 16 December. Volume and sales were also helped by a full three months contribution from the wine distillate business. A temporary market price decline caused SWA to reduce sales of wine distillate to almost zero during Q1 19/20. Following a price recovery, sales of this product resumed during Q2 19/20. (p.t.o.)

# **FINANCIAL HISTORY & PROJECTIONS**

	2016/17	2017/18	2018/19	2019/20	2020/21E	2021/22E
Revenue (€m)	296.06	324.53	337.16	338.21	339.35	353.58
Y-o-y growth	1.0%	9.6%	3.9%	0.3%	0.3%	4.2%
EBIT (€m)	22.18	23.83	22.98	18.97	20.92	22.45
EBIT margin	7.5%	7.3%	6.8%	5.6%	6.2%	6.3%
Net income (€m)	11.50	11.12	10.89	7.62	10.13	10.82
EPS (diluted) (€)	1.45	1.40	1.38	0.96	1.28	1.37
DPS (€)	0.48	0.50	0.50	0.40	0.40	0.50
FCF (€m)	10.40	8.80	9.27	0.23	25.15	18.13
Net gearing	25.3%	23.3%	20.9%	35.9%	25.0%	18.7%
Liquid assets (€m)	5.70	7.76	9.53	6.02	6.79	3.54

# RISKS

Risks to our price target include, but are not limited to: intensification of price pressure in Germany; currency volatility on the group's East Central Europe markets.

## **COMPANY PROFILE**

Schloss Wachenheim AG is one of the world's largest producers of sparkling wine. The company is the number three producer in its home market of Germany (36% of 2019/20 group sales) and number one in France with a 40% market share. Some 38% of group sales are generated in East Central Europe through the 61%-owned subsidiary, Ambra.

MARKET DATA	As of 18 Feb 2021
Closing Price	€ 14.80
Shares outstanding	7.92m
Market Capitalisation	€ 117.22m
52-week Range	€ 11.25 / 16.50
Avg. Volume (12 Months)	2,235

Multiples	2019/20	2020/21E	2021/22E
P/E	15.4	11.6	10.8
EV/Sales	0.6	0.6	0.5
EV/EBIT	9.9	9.0	8.4
Div. Yield	2.7%	2.7%	3.4%

# STOCK OVERVIEW



COMPANY DATA	As of 31 Dec 2021
Liquid Assets	€ 8.41m
Current Assets	€ 199.80m
Intangible Assets	€ 93.03m
Total Assets	€ 391.50m
Current Liabilities	€ 131.51m
Shareholders' Equity	€ 172.58m

# **SHAREHOLDERS**

Günther Reh AG 70.1% Free float 29.9%

Figure 1: Q2 20/21 results versus our forecasts

€m	Q2 20/21A	Q2 20/21E	Δ	Q2 19/20A	Δ
Sales	117.9	115.5	2.1%	118.6	-0.6%
by region					
Germany	43.5	42.0	3.7%	39.1	11.3%
France	22.4	22.0	1.9%	25.3	-11.3%
East Central Europe	54.6	54.0	1.0%	56.1	-2.8%
Eliminations	-2.6	-2.5	n.a.	-1.9	n.a.
EBIT	15.6	14.5	7.7%	12.7	23.2%
margin (%)	13.2%	12.6%	-	10.7%	-
by region					
Germany	4.4	3.5	26.1%	2.5	73.7%
margin (%)	10.1%	8.3%	-	6.5%	-
France	0.8	0.5	52.4%	-1.1	n.a.
margin (%)	3.4%	2.3%	-	-4.3%	-
East Central Europe	10.4	10.5	-0.5%	11.1	-6.0%
margin (%)	19.1%	19.4%	-	19.8%	-
Other/eliminations	0.0	0.0	n.a.	0.1	n.a.
Net profit	7.1	6.6	7.7%	5.4	31.1%
<b>EPS</b> (€)	0.89	0.83	7.7%	0.68	31.1%

Source: SWA; First Berlin Equity Research estimates

A shift in the product mix caused the segment's gross margin to narrow to 42.5% (Q2 19/20: 43.1%). However, EBIT jumped to €4.4m (Q2 19/20: €2.5m) as the margin widened to 10.1% (Q2 19/20: 6.5%). Profitability was boosted by stable personnel costs and a reduction in other operating expenses, part of which was attributable to lower advertising expenses.

In France EBIT rose despite 11.3% sales decline In France volume retreated 17.9% to 15.1m bottles (Q2 19/20: 18.3m bottles). Domestic volume fell as the French authorities imposed a hard lockdown from the end of October - six weeks ahead of similar measures in Germany. The pandemic also reduced segment exports. Russia and the USA were the biggest contributors to the decline in export volume. Business in Russia was additionally hampered by the 22% depreciation of the ruble against the euro between Q2 19/20 and Q2 20/21. A shift in the product mix restricted the decline in segment sales to 11.3% to €22.4m (Q2 19/20: €25.3m) and also widened the gross margin to 39.2% (Q2 19/20: 36.8%). Segment EBIT came in at €0.8m (Q2 19/20: €-1.1m) as management moved to reduce operating costs. Advertising expenditure in H1 20/21 was €1.7m below the level of the prior year period.

Zloty depreciation contributed to East Central Europe sales decline The pandemic also crimped business in East Central Europe where volume fell 0.6% to 34.8m bottles (Q2 19/20: 35.0m bottles). Sales fell 2.8% to €54.6m (Q2 19/20: €56.1m). The gross margin narrowed slightly to 42.7% (Q2 19/20: 43.8%) due to changes in the product mix and also the 4.9% depreciation of the zloty against the euro between Q2 19/20 and Q2 20/21. Segment EBIT was €10.4m (Q2 19/20: €11.1m) equivalent to a margin of 19.1% (Q2 19/20: 19.8%). Advertising expenditure was below the prior year period, but personnel costs rose.

Acquisition of EISBERG brand looks promising Earlier this month SWA acquired EISBERG, the leading UK alcohol-free wine brand, from Halewood International for €3.6m. As the German market leader in alcohol-free wine, sparkling wine and cocktails, SWA has a deep fund of expertise in this segment. SWA has also acted as bottler for the EISBERG product range for over 20 years. The EISBERG product range comprises five still and two sparkling wines which are available at almost all large retailers in the UK. Annual volume is around 2m bottles. The UK market for alcohol-free and alcohol-reduced wines currently has a volume of more than 7 million bottles, having grown by over 20% during the past year.



In addition to direct participation in this growing market, SWA sees the investment as a basis on which to build new UK marketing channels for selected products from its German, French and East Central European segments. Halewood International's sale of EISBERG was motivated by its strategic decision to concentrate more strongly on its spirits business.

End December 2020 net gearing at 33.7% (December 2019: 40.0%) Q2 20/21 cash flow before changes in working capital climbed 8.4% to €16.2m (Q2 19/20: €14.9m). Operating cashflow jumped to €7.2m (Q2 19/20: €-3.6m) due largely to an €11m y-o-y reduction in receivables. Cash outflow from investing was little changed at €2.1m (Q2 19/20: €1.9m). Free cashflow came in at €5.1m (€-5.5m). Dividend payments to SWA shareholders and minority shareholders in the Polish subsidiaries amounted to €5.3m (Q2 19/20: €5.9m). SWA took on new interest bearing liabilities of €2.2m in Q2 20/21. Net debt including pension liabilities rose during the quarter by €3.6m to €71.0m, equivalent to net gearing of 33.7% (Q2 19/20: net debt including pension liabilities of €80.3m and net gearing of 40.0%).

Buy recommendation maintained; price target raised from €20.00 to €21.00 We have raised our 2020/21 forecasts (see figure 2) in response to the robust Q2 performance and management's upward revision of full-year guidance for EBIT and profit before minorities. Our overall sales and profits forecasts for 2021/22 are little changed. We now see fair value for the share at €21.00 (previously: €20.00). We maintain our Buy recommendation.

Figure 2: Changes to our forecasts

		2020/21E			2021/22E	
All figures in €m	old	new	$\Delta$	old	new	Δ
Sales	336.87	339.35	0.7%	350.21	353.58	1.0%
by region:						
Germany	125.87	134.62	6.9%	130.28	140.67	8.0%
France	84.18	75.30	-10.6%	86.71	78.31	-9.7%
East Central Europe	133.20	136.57	2.5%	139.86	142.03	1.6%
Eliminations	-6.38	-7.13	-	-6.64	-7.43	-
EBIT	18.03	20.92	16.0%	22.39	22.45	0.3%
Margin	4.9%	6.2%	-	4.9%	6.3%	-
by region:						
Germany	1.89	4.95	161.6%	3.26	3.52	7.9%
margin (%)	0.0%	3.7%	-	0.0%	2.5%	-
France	3.79	3.51	-7.4%	4.77	4.31	-9.7%
margin (%)	4.0%	4.7%	-	4.0%	5.5%	-
East Central Europe	12.39	12.47	0.7%	14.41	14.63	1.5%
margin (%)	9.0%	9.1%	-	9.0%	10.3%	-
Eliminations	-0.03	-0.01	n.a.	-0.04	-0.01	n.a.
Net profit before minorities	12.58	14.81	17.7%	16.26	16.30	0.3%
Net profit after minorities	7.94	10.13	27.7%	10.86	10.82	-0.4%
EPS €	1.00	1.28	27.9%	1.37	1.37	-0.3%

Source: First Berlin Equity Research estimates

Schloss Wachenheim AG

# **DCF MODEL**

19 February 2021

All figures in EUR 000s	2020/21E	2021/22E	2022/23E	2023/24E	2024/25E	2025/26E	2026/27E	2027/28E	2028/29E	2029/30E	FY 30/31E
Net sales	339,347	353,580	371,286	381,022	388,146	395,531	401,651	407,943	414,413	421,065	427,906
NOPLAT	16,109	17,284	17,761	18,519	19,065	19,632	19,681	20,146	20,625	20,360	20,843
+ depreciation & amortisation	-14,418	-15,023	-15,775	-16,189	-16,492	-16,805	-17,065	-17,333	-17,608	-17,890	-18,181
Net operating cash flow	30,527	32,307	33,537	34,708	35,557	36,438	36,747	37,479	38,232	38,250	39,024
- total investments (CAPEX and WC)	-4,222	-13,345	-27,358	-17,887	-18,902	-20,143	-20,245	-20,190	-19,711	-20,044	-20,385
Capital expenditures	-14,007	-15,182	-22,930	-15,186	-17,116	-17,844	-18,249	-18,137	-17,599	-17,870	-18,148
Working capital	9,785	1,837	-4,427	-2,701	-1,786	-2,299	-1,995	-2,053	-2,113	-2,174	-2,238
Free cash flows (FCF)	26,305	18,962	6,179	16,821	16,655	16,295	16,502	17,289	18,521	18,206	18,639
PV of FCF's	25,595	17,103	5,167	13,039	11,968	10,856	10,192	9,899	9,831	8,958	8,502

All figures in EUR 000s	
PV of FCFs in explicit period (2020/21-2034/35)*	161,849
PV of FCFs in terminal period	112,780
Enterprise value (EV)	274,629
Average net debt (most recent four quarters)	-69,918
Investments / minority interests	-38,364
Shareholder value	166 347

Fair value per share in EUR	21.00									
						Terminal (	growth rate			
WACC	7.9%			0.5%	1.0%	1.5%	2.0%	2.5%	3.0%	3.5%
Cost of equity	9.7%		5.9%	32.20	33.62	35.37	37.57	40.42	44.26	49.73
Pre-tax cost of debt	3.0%		6.4%	28.20	29.23	30.48	32.01	33.94	36.44	39.82
Tax rate	23.0%	O	6.9%	24.84	25.60	26.50	27.59	28.93	30.62	32.81
After-tax cost of debt	2.3%	ACC	7.4%	21.97	22.54	23.21	23.99	24.94	26.11	27.58
Share of equity capital	70.0%	>	7.9%	19.51	19.94	20.43	21.00	21.69	22.51	23.52
Share of debt capital	30.0%		8.4%	17.37	17.69	18.06	18.48	18.97	19.56	20.27
			8.9%	15.50	15.74	16.01	16.32	16.68	17.10	17.61
Price target in EUR	21.00		9.4%	13.84	14.02	14.22	14.45	14.72	15.02	15.38

<sup>\*</sup>for layout purposes the model shows numbers only to 2030/31 but runs until 2034/35



19 February 2021

All figures in €000s	FY 15/16	FY 16/17	FY 17/18	FY 18/19	FY 19/20	FY 20/21E	FY 21/22E
Revenues	293,175	296,062	324,527	337,159	338,212	339,347	353,580
Change in inventories	-3,678	257	3,341	107	240	0	0
Cost of materials	-167,105	-169,778	-190,920	-191,505	-192,653	-193,089	-199,419
Gross Profit	122,392	126,541	136,948	145,761	145,799	146,259	154,161
Other operating income	4,872	4,582	7,994	3,981	5,117	5,134	5,350
Personnel expenses	-43,326	-43,593	-50,249	-53,303	-56,274	-57,010	-57,280
Depreciation	-7,665	-7,844	-9,171	-9,447	-14,401	-14,418	-15,023
Other operating expenses	-55,944	-57,505	-61,694	-64,016	-61,272	-59,043	-64,761
Operating Income (EBIT)	20,329	22,181	23,828	22,976	18,969	20,921	22,447
Associates	78	-6	-1	-27	0	0	0
Net interest income	-964	-1,102	-1,554	-1,291	-1,818	-1,687	-1,272
Pretax profit (EBT)	19,443	21,073	22,273	21,658	17,151	19,234	21,175
Taxes	-5,897	-5,361	-5,900	-5,657	-4,160	-4,424	-4,870
Net profit before minorities	13,546	15,712	16,373	16,001	12,991	14,810	16,304
Minorities	-3,361	-4,211	-5,258	-5,111	-5,376	-4,677	-5,486
Net attributable profit	10,185	11,501	11,115	10,890	7,615	10,133	10,819
EPS (€)	1.29	1.45	1.40	1.38	0.96	1.28	1.37
EBITDA	27,994	30,025	32,999	32,423	33,370	35,339	37,470
Ratios							
Gross margin	41.7%	42.7%	42.2%	43.2%	43.1%	43.1%	43.6%
EBIT margin on revenues	6.9%	7.5%	7.3%	6.8%	5.6%	6.2%	6.3%
EBITDA margin on revenues	9.5%	10.1%	10.2%	9.6%	9.9%	10.4%	10.6%
Net margin on revenues	4.6%	5.3%	5.0%	4.7%	3.8%	4.4%	4.6%
Tax rate	30.3%	25.4%	26.5%	26.1%	24.3%	23.0%	23.0%
Expenses as % of revenues							
Personnel costs	-14.8%	-14.7%	-15.5%	-15.8%	-16.6%	-16.8%	-16.2%
Depreciation	-2.6%	-2.6%	-2.8%	-2.8%	-4.3%	-4.2%	-4.2%
Other operating expenses	-19.1%	-19.4%	-19.0%	-19.0%	-18.1%	-17.4%	-18.3%
Y-Y Growth							
Revenues	1.6%	1.0%	9.6%	3.9%	0.3%	0.3%	4.2%
Operating income  Net profit before minorities	-1.9% -2.1%	9.1% 16.0%	7.4% -100.0%	-3.6% -2.3%	-17.4% -18.8%	10.3% 14.0%	7.3% 10.1%



All figures in €000s	FY 15/16	FY 16/17	FY 17/18	FY 18/19	FY 19/20	FY 20/21E	FY 21/22E
Assets							
Current assets, total	150,179	155,088	172,510	175,357	179,512	174,610	172,775
Cash and cash equivalents	3,142	5,700	7,760	9,531	6,015	6,787	3,536
Other receivables and short-term assets	5,973	5,508	7,349	7,861	6,854	7,685	8,007
Trade accounts and notes receivables	54,784	56,362	58,697	53,563	51,427	51,547	53,709
Inventories	86,280	87,518	98,704	104,402	115,216	108,591	107,524
Non-Current Assets, total	151,237	158,818	165,328	170,751	193,261	192,045	192,247
Property, plant and equipment	64,447	72,431	70,292	75,744	92,659	91,624	91,224
Goodwill + intangible assets	78,508	78,557	89,145	88,862	93,469	94,093	94,651
Other financial assets	7,733	5,654	5,403	5,051	3,795	3,795	3,795
Deferred taxes + prepaid expenses	549	481	488	1,094	1,822	1,018	1,061
Long term assets for sale	0	1,695	0	0	1,516	1,516	1,516
Total Assets	301,416	313,906	337,838	346,108	372,773	366,655	365,022
Shareholders' equity & debt							
Current Liabilities, total	95,236	97,782	104,645	109,987	117,850	108,913	102,430
Current provisions	3,415	3,020	3,846	4,425	5,661	3,410	3,518
Short-term financial debt	27,198	28,221	25,265	28,099	40,319	28,950	19,149
Trade payables	35,248	37,434	41,423	44,185	41,498	40,722	42,430
Prepayments, deferred charges & other liabilities	29,375	29,107	34,111	33,278	30,372	35,831	37,333
Long term liabilities, total	34,159	32,443	41,626	34,197	50,704	39,853	34,718
Long-term financial debt	23,607	20,982	24,470	20,886	36,705	29,814	24,347
Pension accruals and similar liabilities	3,155	2,970	2,750	2,763	2,396	2,540	2,692
Other long-term debt	557	804	4,919	1,063	1,590	1,018	1,061
Deferred taxes	6,840	7,687	9,487	9,485	10,013	6,481	6,618
Shareholders' equity	143,173	152,431	158,571	165,950	167,773	176,767	181,265
Minority interests	28,848	31,250	32,996	35,974	36,446	41,123	46,609
Total shareholders' equity & debt	301,416	313,906	337,838	346,108	372,773	366,655	365,022
Ratios							
Current ratio (x)	1.58	1.59	1.65	1.59	1.52	1.60	1.69
Quick ratio (x)	0.67	0.69	0.71	0.65	0.55	0.61	0.64
Financial leverage (including pension liabilities)	29.5%	25.3%	23.3%	20.9%	35.9%	25.0%	18.7%
Book value per share (€)	18.08	19.25	20.02	20.95	21.18	22.32	22.88
Net debt (including pension liabilities)	50,818	46,473	44,725	42,217	73,405	54,517	42,653
Return on equity (ROE)	6.0%	6.5%	5.9%	5.5%	3.7%	4.8%	4.9%



# **CASH FLOW STATEMENT**

All figures in €000s	FY 15/16	FY 16/17	FY 17/18	FY 18/19	FY 19/20	FY 20/21E I	FY 21/22E
Net profit before minorities	13,546	15,712	16,373	16,001	12,991	14,810	16,304
Depreciation and amortisation	7,665	7,844	9,171	9,447	14,401	14,418	15,023
Change in working capital	-5,295	-662	-3,128	1,230	-13,229	9,785	1,837
Other	-310	1,775	-1,659	345	-1,204	144	152
Operating cash flow	15,606	24,669	20,757	27,023	12,959	39,157	33,316
CAPEX	-14,050	-14,838	-15,049	-18,092	-13,183	-14,007	-15,182
Fixed asset sales	904	565	3,095	337	458	0	0
Investing cash flow	-13,146	-14,273	-11,954	-17,755	-12,725	-14,007	-15,182
Free cash flow	2,460	10,396	8,803	9,268	234	25,150	18,135
Change in financial liabilities	2,388	-1,602	-479	-750	2,883	-18,260	-15,268
Dividends to shareholders	-3,168	-3,406	-3,802	-3,960	-3,960	-3,168	-3,168
Dividends to susbidiaries of minorities	-2,753	-2,657	-2,920	-2,601	-2,950	-2,950	-2,950
Other	127	0	209	0	0	0	0
Financing cash flow	-3,406	-7,665	-6,992	-7,311	-4,027	-24,378	-21,386
Change in cash	-946	2,731	1,811	1,957	-3,793	772	-3,251
Consolidation; exchange rate effects	93	-173	249	-186	277	0	0
Liquid funds, start of the year	3,995	3,142	5,700	7,760	9,531	6,015	6,787
Liquid funds, end of the year	3,142	5,700	7,760	9,531	6,015	6,787	3,536
Free cash flow per share (€)	0.31	1.31	1.11	1.17	0.03	3.18	2.29
Y-Y growth							
Operating cash flow	-53.2%	58.1%	-15.9%	30.2%	-52.0%	202.2%	-14.9%
Free cash flow	-91.4%	322.6%	-15.3%	5.3%	-97.5%	10647.9%	-27.9%
Financial cash flow	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.



# **Imprint / Disclaimer**

## First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:

First Berlin Equity Research GmbH Mohrenstr. 34 10117 Berlin Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680 Fax: +49 (0) 30-80 93 9 687 E-Mail: <u>info@firstberlin.com</u>

Amtsgericht Berlin Charlottenburg HR B 103329 B

UST-ld.: 251601797

Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV

First Berlin Equity Research GmbH

Authored by: Simon Scholes, Analyst

All publications of the last 12 months were authored by Simon Scholes.

Company responsible for preparation: First Berlin Equity Research GmbH, Mohrenstraße 34, 10117

The production of this recommendation was completed on 19 February 2021 at 11:40

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

**Copyright**® **2021 First Berlin Equity Research GmbH** No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

# **CONFLICTS OF INTEREST**

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of Schloss Wachenheim AG the following relationships and circumstances are exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Schloss Wachenheim AG for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0,5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;



- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of Schloss Wachenheim AG the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Schloss Wachenheim AG for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

### PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

#### AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

## **ASSET VALUATION SYSTEM**

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

### **ASSET RECOMMENDATION**

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category		1	2
Current market capitalisation (in €)		0 - 2 billion	> 2 billion
Strong Buy <sup>1</sup>	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

<sup>&</sup>lt;sup>1</sup> The expected price trend is in combination with sizable confidence in the quality and forecast security of management

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of  $\in 0 - \in 2$  billion, and Category 2 companies have a market capitalisation of  $> \in 2$  billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

# **RISK ASSESSMENT**

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

# **RECOMMENDATION & PRICE TARGET HISTORY**

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	19 July 2007	€10.00	Hold	€10.75
244	$\downarrow$	$\downarrow$	<b>↓</b>	<b>↓</b>
45	24 September 2019	€16.55	Add	€22.30
46	19 November 2019	€17.75	Add	€22.20
47	27 February 2020	€15.55	Buy	€20.30
48	15 May 2020	€12.40	Buy	€18.90
49	29 September 2020	€15.70	Buy	€20.00
50	18 November 2020	€15.30	Buy	€20.00
51	Today	€14.80	Buy	€21.00

# INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.



# **UPDATES**

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

#### SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

### Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

### **EXCLUSION OF LIABILITY (DISCLAIMER)**

# RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

## **RELIABILITY OF ESTIMATES AND FORECASTS**

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

# INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

# NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

# NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

# **DUPLICATION**

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

# **SEVERABILITY**

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

# APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

# NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

# **QUALIFIED INSTITUTIONAL INVESTORS**

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.